BAM15

A small-molecule mitochondrial protonophore uncoupler, not a peptide, identified in a 2014 screen for uncouplers that spare the plasma membrane and studied in mouse models of diet-induced obesity, kidney ischemia, and sepsis.

Also referenced as: BAM-15, BAM 15, N5,N6-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine

Also appears in: Weight loss

What is BAM15?

BAM15 is a synthetic small molecule, N5,N6-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine (C16H10F2N6O, 340.29 g/mol, PubChem CID 565708), that acts as a mitochondrial protonophore uncoupler. It is not a peptide: it is a fluorinated oxadiazolopyrazine — also written as a furazano[3,4-b]pyrazine — found by screening a small-molecule chemical library, work led from the Department of Pharmacology at the University of Virginia with the synthetic chemistry done at Virginia Tech. The published report names the hit “BAM15” without expanding the prefix, so the label carries no structural meaning.

It appears in the research-compound market alongside peptides because its mouse data on fat mass and insulin sensitivity overlap with the interests of that market, and because it is orally bioavailable rather than injected.

How it works

Mitochondrial uncouplers are lipophilic weak acids that carry protons across the inner mitochondrial membrane independently of ATP synthase, dissipating the proton gradient so that nutrient oxidation continues without matching ATP production. BAM15 was selected for doing this with less off-target activity than older uncouplers:

• Selective for the mitochondrial inner membrane — BAM15 uncoupled mitochondria without depolarizing the plasma membrane, and compared against FCCP, an uncoupler of equal potency, it stimulated a higher maximum rate of mitochondrial respiration and was less cytotoxic in cultured cells. Avoiding the plasma-membrane and mitochondrial-inhibitory off-target activity of FCCP and 2,4-dinitrophenol was the explicit goal of the screen (Kenwood et al., Molecular Metabolism, 2014)
• Increased nutrient oxidation without appetite change — in diet-induced obese mice, orally delivered BAM15 increased nutrient oxidation and decreased body fat mass while food intake, lean body mass, body temperature, and hematological and biochemical markers of toxicity were unchanged; hyperinsulinemic-euglycemic clamps showed improved insulin sensitivity in multiple tissue types (Alexopoulos et al., Nature Communications, 2020)
• Sustained AMPK activation — BAM15 enhanced mitochondrial respiratory kinetics, improved insulin action, and stimulated nutrient uptake in vitro through sustained activation of AMPK; the same group reported stimulated energy expenditure in mice and glycemic benefits that were independent of weight loss and attributable to drug targeting of lipid-rich tissues (Axelrod et al., EMBO Molecular Medicine, 2020). In rat mesenteric arteries and A10 vascular smooth muscle cells, BAM15 relaxed phenylephrine-induced constriction and activated AMPK more potently than CCCP, niclosamide, metformin, or AICAR (Tai et al., Acta Pharmaceutica Sinica B, 2018)
• Reactive oxygen species: direction depends on the tissue — the class rationale is that lowering the proton motive force reduces mitochondrial superoxide output, and in the sepsis work BAM15 dissipated the proton gradient without generating mitochondrial ROS, which is why it was taken into ischemia-reperfusion and sepsis models (Kenwood et al., 2014; Tsuji et al., Journal of Clinical Investigation, 2023). That is not universal: in A10 vascular smooth muscle cells BAM15 increased mitochondrial ROS production along with mitochondrial fission and depolarization (Tai et al., 2018), so “antioxidant uncoupler” is a model-specific result rather than a settled property

Research status

All BAM15 efficacy data are preclinical. Key published work:

• Kenwood et al. (2014) reported the identification and validation of BAM15 and showed that it is bioactive in vivo, dose-dependently protecting mice from acute renal ischemia-reperfusion injury (Molecular Metabolism, 3(2):114–123)
• Alexopoulos et al. (2020) showed that orally bioavailable BAM15 reversed diet-induced obesity and insulin resistance in mice, decreased hepatic fat and inflammatory lipids, and did not move toxicity markers over the study period (Nature Communications, 11:2397)
• Axelrod et al. (2020) independently reported that BAM15-treated C57BL/6J mice resisted weight gain and had improved body composition and glycemic control, the first phenotypic characterization of the compound (EMBO Molecular Medicine, 12(7):e12088)
• Tsuji et al. (2023) injected BAM15 at 0, 6, or 12 hours after cecal ligation and puncture in mice also given fluids and antibiotics: it reduced mortality even when started at 12 hours, when the animals were already ill, and reduced kidney damage and splenic apoptosis. Plasma and urinary mitochondrial DNA fell with dosing at 0 or 6 hours, and depleting neutrophils abolished the benefit (Journal of Clinical Investigation, 133(7):e152401)
• A stream of rodent and cell studies has extended the compound to LPS-induced inflammation, atherosclerosis, hepatic lipid metabolism, breast cancer models, and oocyte quality in obese mice (Ma et al., Protein & Cell, 2026); these remain mechanistic and preclinical

Two of the obesity papers carry a commercial disclosure worth reading alongside the results: senior authors on the Nature Communications work hold a financial interest in Continuum Biosciences, a company developing mitochondrial uncouplers as therapeutics.

No human trials. A ClinicalTrials.gov search for “BAM15” returns exactly one record, and it is unrelated — a monoclonal-antibody COVID-19 study whose text matches on “bamlanivimab” (NCT04634409). No investigational new drug filing, approval, complete response letter, or discontinuation has been disclosed for BAM15 in any jurisdiction as of October 2026. The discovering groups have continued to publish BAM15 analogs designed for better exposure and potency (for example Quinlan et al., Bioorganic & Medicinal Chemistry, 2025, 118:118045), which indicates that BAM15 itself is treated as a tool compound and starting scaffold rather than a clinical candidate.

Common dosage forms

On the research market BAM15 is supplied as an oral product rather than an injectable. Research-market listings are mostly capsules and tablets in 60-count bottles, most commonly labeled 25 mg or 50 mg per unit, and it is frequently sold in fixed capsule blends with other oral research compounds such as SLU-PP-332. Separately from that market, laboratory reagent catalogs supply milligram quantities of BAM15 powder for dissolution in DMSO for in vitro respirometry, which is its original use.

Key considerations

• Not a peptide and not a drug product in any country; it is a laboratory tool compound sold on the research market with no regulatory review of purity, stability, or human pharmacology. The Research Market status reflects the absence of US approval or any development program aimed at approval.
• Preclinical only: every efficacy and tolerability signal comes from mice, rats, or cultured cells; there are no human pharmacokinetic, dose-finding, or safety data, and no registered clinical trials.
• The DNP comparison is about cell-level selectivity, not demonstrated human safety. 2,4-dinitrophenol, the historic weight-loss uncoupler, has a narrow therapeutic index and kills through hyperthermia, tachycardia, diaphoresis, and tachypnea; the FDA labeled it unfit for human consumption in 1938 and medical prescription stopped after that year, yet a 2011 review counted 62 deaths in the published literature, with illicit internet sales continuing (Grundlingh et al., Journal of Medical Toxicology, 2011, 7(3):205–212). BAM15 spared the plasma membrane and did not raise body temperature in mice, but uncouplers as a class have a dose-dependent ceiling beyond which ATP depletion and heat production become dangerous, and that ceiling has never been mapped in humans.
• Pharmacokinetics are a known gap: the mouse studies delivered BAM15 continuously in chow or by repeated injection, and the discoverers’ own medicinal-chemistry program has focused on analogs with better exposure, so single-dose oral capsule formats are not equivalent to the published experimental conditions.
• Naming: “BAM15” is written variously as BAM-15 or BAM 15, and the original paper used an alternate ring notation, (2-fluorophenyl){6-(2-fluorophenyl)amino}amine, for the same molecule. It is unrelated to the BAM peptides of bovine adrenal medulla origin (BAM12P, BAM22P) and to bamlanivimab, both of which produce false matches in registry and literature searches.